A key feature of this therapy is its ability to initiate a self-sustaining cycle of immunity: CAR-M phagocytosis primes tumor-specific T cell responses, which are essential for long-term efficacy as demonstrated by CD8+ T cell depletion, and these activated T cells in turn sustain CAR-M activity. This evidence concerns the gene CD8A and neoplasm.